4//SEC Filing
COLUMN GROUP II, LP 4
Accession 0001209191-20-025998
CIK 0001796280other
Filed
Apr 27, 8:00 PM ET
Accepted
Apr 28, 5:42 PM ET
Size
22.0 KB
Accession
0001209191-20-025998
Insider Transaction Report
Form 4
Column Group II GP, LP
10% OwnerOther
Transactions
- Conversion
Common Stock
2020-04-28+3,500,000→ 3,575,000 total - Conversion
Common Stock
2020-04-28+416,666→ 4,616,666 total - Conversion
Series B Preferred Stock
2020-04-28−625,000→ 0 total→ Common Stock (625,000 underlying) - Conversion
Series D Preferred Stock
2020-04-28−151,515→ 0 total→ Common Stock (151,515 underlying) - Conversion
Series A Preferred Stock
2020-04-28−3,500,000→ 0 total→ Common Stock (3,500,000 underlying) - Conversion
Common Stock
2020-04-28+625,000→ 4,200,000 total - Conversion
Common Stock
2020-04-28+151,515→ 4,768,181 total - Conversion
Series C Preferred Stock
2020-04-28−416,666→ 0 total→ Common Stock (416,666 underlying)
GOEDDEL DAVID V
10% OwnerOther
Transactions
- Conversion
Common Stock
2020-04-28+625,000→ 4,200,000 total - Conversion
Common Stock
2020-04-28+151,515→ 4,768,181 total - Conversion
Series A Preferred Stock
2020-04-28−3,500,000→ 0 total→ Common Stock (3,500,000 underlying) - Conversion
Series B Preferred Stock
2020-04-28−625,000→ 0 total→ Common Stock (625,000 underlying) - Conversion
Series C Preferred Stock
2020-04-28−416,666→ 0 total→ Common Stock (416,666 underlying) - Conversion
Common Stock
2020-04-28+416,666→ 4,616,666 total - Conversion
Common Stock
2020-04-28+3,500,000→ 3,575,000 total - Conversion
Series D Preferred Stock
2020-04-28−151,515→ 0 total→ Common Stock (151,515 underlying)
COLUMN GROUP II, LP
10% Owner
Transactions
- Conversion
Common Stock
2020-04-28+3,500,000→ 3,575,000 total - Conversion
Series A Preferred Stock
2020-04-28−3,500,000→ 0 total→ Common Stock (3,500,000 underlying) - Conversion
Series B Preferred Stock
2020-04-28−625,000→ 0 total→ Common Stock (625,000 underlying) - Conversion
Series D Preferred Stock
2020-04-28−151,515→ 0 total→ Common Stock (151,515 underlying) - Conversion
Common Stock
2020-04-28+625,000→ 4,200,000 total - Conversion
Common Stock
2020-04-28+416,666→ 4,616,666 total - Conversion
Common Stock
2020-04-28+151,515→ 4,768,181 total - Conversion
Series C Preferred Stock
2020-04-28−416,666→ 0 total→ Common Stock (416,666 underlying)
Footnotes (2)
- [F1]Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.
- [F2]The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Documents
Issuer
Oric Pharmaceuticals, Inc.
CIK 0001796280
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001600420
Filing Metadata
- Form type
- 4
- Filed
- Apr 27, 8:00 PM ET
- Accepted
- Apr 28, 5:42 PM ET
- Size
- 22.0 KB